Jonathan W. Stocker

2.2k total citations · 1 hit paper
19 papers, 1.6k citations indexed

About

Jonathan W. Stocker is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Jonathan W. Stocker has authored 19 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 10 papers in Molecular Biology and 9 papers in Hematology. Recurrent topics in Jonathan W. Stocker's work include Hemoglobinopathies and Related Disorders (11 papers), Blood groups and transfusion (6 papers) and Ion channel regulation and function (5 papers). Jonathan W. Stocker is often cited by papers focused on Hemoglobinopathies and Related Disorders (11 papers), Blood groups and transfusion (6 papers) and Ion channel regulation and function (5 papers). Jonathan W. Stocker collaborates with scholars based in United States, Jamaica and Italy. Jonathan W. Stocker's co-authors include Kenneth I. Ataga, Wally R. Smith, Abdullah Kutlar, Russell P. Rother, Scott A. Rollins, Darla Liles, Ofelia Álvarez, Julie Kanter, Troy H. Guthrie and Rodolfo Delfini Cançado and has published in prestigious journals such as New England Journal of Medicine, Journal of Neuroscience and Blood.

In The Last Decade

Jonathan W. Stocker

19 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

2016 595 citations Kenneth I. Ataga, Abdullah Kutlar et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Jonathan W. Stocker

Since Specialization

Citations

This map shows the geographic impact of Jonathan W. Stocker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan W. Stocker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan W. Stocker more than expected).

Fields of papers citing papers by Jonathan W. Stocker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan W. Stocker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan W. Stocker. The network helps show where Jonathan W. Stocker may publish in the future.

Co-authorship network of co-authors of Jonathan W. Stocker

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan W. Stocker. A scholar is included among the top collaborators of Jonathan W. Stocker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan W. Stocker. Jonathan W. Stocker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease breakdown → 2016 ·New England Journal of Medicine ·Kenneth I. Ataga, Abdullah Kutlar, Julie Kanter, Darla Liles, Rodolfo Delfini Cançado, João Ricardo Friedrisch, Troy H. Guthrie, Jennifer Knight‐Madden, Ofelia Álvarez, Victor R. Gordeuk, Sandra Gualandro, Marina Colella, Wally R. Smith, Scott A. Rollins, Jonathan W. Stocker, Russell P. Rother	595
2	SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises 2016 ·Blood ·Kenneth I. Ataga, Abdullah Kutlar, Julie Kanter, Darla Liles, Rodolfo Delfini Cançado, João Ricardo Friedrisch, Troy H. Guthrie, Jennifer Knight‐Madden, Ofelia Álvarez, Victor R. Gordeuk, Sandra Fátima Menosi Gualandro, (unknown), Wally R. Smith, Scott A. Rollins, Jonathan W. Stocker, Russell P. Rother	14
3	The trials and hopes for drug development in sickle cell disease 2015 ·British Journal of Haematology ·Kenneth I. Ataga, Jonathan W. Stocker	26
4	Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease 2013 ·Blood ·Jonathan W. Stocker, (unknown), Ziad Kawar, (unknown), (unknown), Scott A. Rollins, Russell P. Rother	8
5	Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso‐occlusive crises in patients with sickle cell disease: a phase III randomized, placebo‐controlled, double‐blind study of the gardos channel blocker senicapoc (ICA‐17043) 2011 ·British Journal of Haematology ·Kenneth I. Ataga, Marvin Reid, Samir K. Ballas, Zahida Yasin, Carolyn Bigelow, (unknown), Wally R. Smith, Frederic Galactéros, Abdullah Kutlar, J. Heyward Hull, Jonathan W. Stocker, (unknown)	160
6	Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia 2009 ·Expert Opinion on Investigational Drugs ·Kenneth I. Ataga, Jonathan W. Stocker	50
7	Novel Inhibitors of the Gardos Channel for the Treatment of Sickle Cell Disease 2008 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Jonathan W. Stocker, (unknown), (unknown), (unknown), (unknown), Lucia De Franceschi	53
8	Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia 2008 ·Blood ·Kenneth I. Ataga, Wally R. Smith, Laura M. De Castro, Paul Swerdlow, Yogen Saunthararajah, Oswaldo Castro, Elliott Vichinsky, Abdullah Kutlar, Eugene P. Orringer, Greg C. Rigdon, Jonathan W. Stocker	180
9	Dose‐Escalation Study of ICA‐17043 in Patients with Sickle Cell Disease 2006 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Kenneth I. Ataga, Eugene P. Orringer, Lori Styles, Elliott Vichinsky, Paul Swerdlow, George A. Davis, Philip A. DeSimone, Jonathan W. Stocker	50
10	A 48-Week Open-Label Study of Senicapoc (ICA-17043), a Gardos Channel Blocker, in Patients with Sickle Cell Disease. 2006 ·Blood ·Paul Swerdlow, Kenneth I. Ataga, Wally R. Smith, Yogen Saunthararajah, Jonathan W. Stocker	5
11	Maurotoxin: A Potent Inhibitor of Intermediate Conductance Ca2+-Activated Potassium Channels 2003 ·Molecular Pharmacology ·Neil A. Castle, (unknown), (unknown), Ziad Fajloun, Jonathan W. Stocker, Jean‐Marc Sabatier	77
12	ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice 2003 ·Blood ·Jonathan W. Stocker, Lucia De Franceschi, (unknown), Roberto Corrocher, Yves Beuzard, Carlo Brugnara	174
13	GABA-Mediated Inhibition Between Amacrine Cells in the Goldfish Retina 2000 ·Journal of Neurophysiology ·Shuichi Watanabe, Amane Koizumi, (unknown), Jonathan W. Stocker, Akimichi Kaneko	30
14	Preferential Interaction of ω-Conotoxins with Inactivated N-type Ca²⁺Channels 1997 ·Journal of Neuroscience ·Jonathan W. Stocker, László Nádasdi, Richard W. Aldrich, Richard W. Tsien	64
15	Photosynthetic reaction center mutagenesis via chimeric rescue of a non-functional Rhodobacter capsulatus puf operon with sequences from Rhodobacter sphaeroides 1993 ·Photosynthesis Research ·Aileen K. W. Taguchi, Jonathan W. Stocker, Steven G. Boxer, Neal W. Woodbury	2
16	Stark effect spectroscopy of the 1250 nm P+ band of Rhodobacter sphaeroides reaction centers and related model compounds 1993 ·Biochimica et Biophysica Acta (BBA) - Bioenergetics ·Jonathan W. Stocker, Stephan J. Hug, Steven G. Boxer	13
17	Biochemical characterization and electron-transfer reactions of sym1, a Rhodobacter capsulatus reaction center symmetry mutant which affects the initial electron donor 1992 ·Biochemistry ·Aileen K. W. Taguchi, Jonathan W. Stocker, R. G. Alden, Timothy P. Causgrove, Jeffrey M. Peloquin, Steven G. Boxer, Neal W. Woodbury	62
18	Spectroscopic and redox properties of sym1 and (M)F195H: Rhodobacter capsulatus reaction center symmetry mutants which affect the initial electron donor 1992 ·Biochemistry ·Jonathan W. Stocker, Aileen K. W. Taguchi, H. A. Murchison, Neal W. Woodbury, Steven G. Boxer	33
19	Stark effect spectroscopy of bacteriochlorophyll in light-harvesting complexes from photosynthetic bacteria 1991 ·Biochimica et Biophysica Acta (BBA) - Bioenergetics ·David Gottfried, Jonathan W. Stocker, Steven G. Boxer	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact